vs
Side-by-side financial comparison of GRAIL, Inc. (GRAL) and MDxHealth SA (MDXH). Click either name above to swap in a different company.
GRAIL, Inc. is the larger business by last-quarter revenue ($43.6M vs $19.8M, roughly 2.2× MDxHealth SA).
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
MDxHealth SA is a global molecular diagnostics company specializing in non-invasive precision oncology tests focused primarily on urological cancers including prostate and bladder cancer. It operates across key markets in North America and Europe, providing clinicians with actionable diagnostic insights to guide personalized treatment decisions, reduce unnecessary invasive procedures, and improve patient care outcomes.
GRAL vs MDXH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $43.6M | $19.8M |
| Net Profit | $-99.2M | — |
| Gross Margin | — | 60.8% |
| Operating Margin | -285.4% | -33.3% |
| Net Margin | -227.5% | — |
| Revenue YoY | 14.0% | — |
| Net Profit YoY | -2.2% | — |
| EPS (diluted) | $-2.37 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $43.6M | — | ||
| Q3 25 | $36.2M | — | ||
| Q2 25 | $35.5M | — | ||
| Q1 25 | $31.8M | $19.8M | ||
| Q4 24 | $38.3M | — | ||
| Q3 24 | $28.7M | — | ||
| Q2 24 | $32.0M | — | ||
| Q1 24 | $26.7M | $14.7M |
| Q4 25 | $-99.2M | — | ||
| Q3 25 | $-89.0M | — | ||
| Q2 25 | $-114.0M | — | ||
| Q1 25 | $-106.2M | — | ||
| Q4 24 | $-97.1M | — | ||
| Q3 24 | $-125.7M | — | ||
| Q2 24 | $-1.6B | — | ||
| Q1 24 | $-218.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 60.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 59.3% |
| Q4 25 | -285.4% | — | ||
| Q3 25 | -346.2% | — | ||
| Q2 25 | -446.9% | — | ||
| Q1 25 | -482.5% | -33.3% | ||
| Q4 24 | -358.0% | — | ||
| Q3 24 | -640.5% | — | ||
| Q2 24 | -5133.8% | — | ||
| Q1 24 | -851.1% | -59.3% |
| Q4 25 | -227.5% | — | ||
| Q3 25 | -245.8% | — | ||
| Q2 25 | -320.7% | — | ||
| Q1 25 | -333.6% | — | ||
| Q4 24 | -253.8% | — | ||
| Q3 24 | -438.7% | — | ||
| Q2 24 | -4958.8% | — | ||
| Q1 24 | -819.3% | — |
| Q4 25 | $-2.37 | — | ||
| Q3 25 | $-2.46 | — | ||
| Q2 25 | $-3.18 | — | ||
| Q1 25 | $-3.10 | — | ||
| Q4 24 | $-1.49 | — | ||
| Q3 24 | $-3.94 | — | ||
| Q2 24 | $-51.06 | — | ||
| Q1 24 | $-7.05 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $249.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.6B | — |
| Total Assets | $2.9B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $249.7M | — | ||
| Q3 25 | $126.9M | — | ||
| Q2 25 | $127.4M | — | ||
| Q1 25 | $133.9M | — | ||
| Q4 24 | $214.2M | — | ||
| Q3 24 | $853.6M | — | ||
| Q2 24 | $958.8M | — | ||
| Q1 24 | $199.7M | — |
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.6B | — | ||
| Q2 24 | $2.7B | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.9B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.7B | — | ||
| Q1 25 | $2.8B | — | ||
| Q4 24 | $3.0B | — | ||
| Q3 24 | $3.1B | — | ||
| Q2 24 | $3.3B | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.8M | — |
| Free Cash FlowOCF − Capex | $-63.9M | — |
| FCF MarginFCF / Revenue | -146.5% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-299.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-63.8M | — | ||
| Q3 25 | $-63.2M | — | ||
| Q2 25 | $-77.0M | — | ||
| Q1 25 | $-95.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-104.6M | — | ||
| Q2 24 | $-171.8M | — | ||
| Q1 24 | $-207.3M | — |
| Q4 25 | $-63.9M | — | ||
| Q3 25 | $-63.6M | — | ||
| Q2 25 | $-77.3M | — | ||
| Q1 25 | $-95.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-105.6M | — | ||
| Q2 24 | $-173.2M | — | ||
| Q1 24 | $-209.8M | — |
| Q4 25 | -146.5% | — | ||
| Q3 25 | -175.8% | — | ||
| Q2 25 | -217.6% | — | ||
| Q1 25 | -298.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -368.4% | — | ||
| Q2 24 | -541.7% | — | ||
| Q1 24 | -785.3% | — |
| Q4 25 | 0.2% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 4.3% | — | ||
| Q1 24 | 9.5% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GRAL
| Screening Revenue | $42.3M | 97% |
| Developmental Services Revenue | $1.3M | 3% |
MDXH
Segment breakdown not available.
